ReviewNature reviews. Immunology2021
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future.
Review in Nature reviews. Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Multitarget Pharmacological Mechanisms and Safety Profiles of Six Ethnobotanically Prioritized Indonesian Medicinal Plants for Cardiometabolic Disorders: A Systematic Review.Drug design, development and therapy · 2026Pooled it
- Decoding Immunometabolic Dynamics of Adipose Tissue in Obesity: Evolving Evidence and Way Forward.ACS pharmacology & translational science · 2026Review
- Artemisinin derivative SM934 targets α-enolase to inhibit PEP-mediated TAK1 stabilization and inflammation.Science China. Life sciences · 2026Article
- The Interplay of Autoimmune Disease, Cancer, and Immunity: Current Understanding and Therapeutic Prospects.International journal of hematology-oncology and stem cell research · 2025Review
- Early-life exercise extends healthspan but not lifespan in mice.Nature communications · 2025Article
- Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease.MedComm · 2025Review
- Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.Virology journal · 2025Review
- Lymphocyte Subset Imbalance in Cardiometabolic Diseases: Are T Cells the Missing Link?International journal of molecular sciences · 2025Review
- The immunology of diabetic cardiomyopathy.Frontiers in endocrinology · 2025Review
- Identification of arachidonic acid metabolism-related diagnostic markers in heart failure based on bioinformatics analysis and machine learning.Frontiers in cardiovascular medicine · 2025Article
- A Multi-Dimensional Approach to Map Disease Relationships Challenges Classical Disease Views.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Immunometabolism in atherosclerotic disorders.Nature cardiovascular research · 2024Review
- Review
- Adipose tissue lymphocytes and obesity.The journal of cardiovascular aging · 2024Article
- Perspective: Pathological transdifferentiation-a novel therapeutic target for cardiovascular diseases and chronic inflammation.Frontiers in cardiovascular medicine · 2024Article
- A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease.Pharmaceutics · 2023Review
- The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications.Aging and disease · 2023Article
- Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy.Cell communication and signaling : CCS · 2023Review
- Immunoprofiling and immunoscoring in cor onary artery disease: From vascular research to the bedside?International journal of cardiology. Heart & vasculature · 2023Article
- Role of angiogenic transdifferentiation in vascular recovery.Frontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic disorders were originally thought to be driven primarily by changes in lipid metabolism that cause the accumulation of lipids in organs, thereby impairing their function. Thus, in the setting of cardiovascular disease, statins - a class of lipid-lowering drugs - have remained the frontline therapy. In the past 20 years, seminal discoveries have revealed a central role of both the innate and adaptive immune system in driving cardiometabolic disorders. As such, it is now appreciated that immune-based interventions may have an important role in reducing death and disability from cardiometabolic disorders. However, to date, there have been a limited number of clinical trials exploring this interventional strategy. Nonetheless, elegant preclinical research suggests that immune-targeted therapies can have a major impact in treating cardiometabolic disease. Here, we discuss the history and recent advancements in the use of immunotherapies to treat cardiometabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.